Item 5.07 Submission of Matters to a Vote of Security Holders.

AbCellera Biologics Inc. (the "Company") held its Annual Meeting of Shareholders (the "Annual Meeting") on June 15, 2023. As of April 17, 2023, the record date for the Annual Meeting, there were 288,653,194 common shares of the Company outstanding and entitled to vote at the Annual Meeting. The Company's shareholders voted on the following matters, which are described in detail in the Company's Definitive Proxy Statement filed with the U.S. Securities and Exchange Commission on April 28, 2023: (i) to elect John S. Montalbano, CFA and Peter Thiel as class III directors of the Company to serve for a three-year term expiring at the Company's annual meeting of shareholders in 2026 and until his or her successor has been elected and qualified ("Proposal 1"), (ii) to ratify the appointment of KPMG LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023 ("Proposal 2"), and (iii) to approve on a non-binding advisory basis, the compensation of the Company's named executive offices, or Say-on-Pay ("Proposal 3").

Proposal 1 The Company's shareholders approved the election of John S. Montalbano, CFA and Peter Thiel as class III directors recommended for election in Proposal 1 at the Annual Meeting. The Company's shareholders voted for the class III directors as follows:



         Nominee                For         Against      Abstain
 John S. Montalbano, CFA    167,257,682    10,997,867    165,946
       Peter Thiel          131,151,160    47,033,189    237,146

The broker non-votes for this Proposal 1 totaled 23,048,328 common shares.

Proposal 2 The Company's shareholders approved Proposal 2. The votes cast at the Annual Meeting were as follows:



     For         Against     Abstain
 200,983,540     299,897     186,386

Proposal 3 The Company's shareholders approved Proposal 3. The votes cast at the Annual Meeting were as follows:



     For         Against      Abstain
 159,440,607    18,625,842    355,046

The broker non-votes for this Proposal 3 totaled 23,048,328 common shares.

No other matters were submitted to or voted on by the Company's shareholders at the Annual Meeting.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses